New inhaled drug hopes to heal lungs in ventilator patients
NCT ID NCT07558538
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a single inhaled dose of a lab-made protein (Rh-KGF-2) in 24 adults with moderate to severe ARDS who are on ventilators. The goal is to see if the drug is safe and tolerable, and to find the right dose. Participants are split into three dose groups, with most getting the drug and a few receiving standard care alone. The study lasts 28 days and tracks side effects, oxygen levels, and lung recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human keratinocyte growth factor-2 (Rh-KGF-2) inhaled powder
What this could lead to
If it works, this could point toward a new treatment to help repair lung damage in ARDS patients on ventilators.
What could go wrong
This is a very early, small trial (24 people) testing only a single dose. It primarily checks safety, not effectiveness, and the drug may cause airway spasms or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ShanghaiZhongshan
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••